THRA, another metabolic gene experimentally shown to interfere with insulin resistance [36], was also frequently co-amplified along with ERBB2 and STARD3. Hence, STARD3 and THRA may represent additional targets for therapeutic interventions in HER2-positive cancers. This evidence concerns the gene ERBB2 and cancer.